Champions Oncology Overview
- Year Founded
-
1985
- Status
-
Public
- Employees
-
306
- Stock Symbol
-
CSBR
- Investments
-
1
- Share Price
-
$8.00
- (As of Wednesday Closing)
Champions Oncology General Information
Description
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Contact Information
Website
www.championsoncology.comCorporate Office
- One University Plaza
- Suite 307
- Hackensack, NJ 07601
- United States
Corporate Office
- One University Plaza
- Suite 307
- Hackensack, NJ 07601
- United States
Champions Oncology Stock Performance
As of 23-Apr-2025, Champions Oncology’s stock price is $8.00. Its current market cap is $109M with 13.8M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.00 | $7.86 | $3.60 - $11.99 | $109M | 13.8M | 43.5K | $0.47 |
Champions Oncology Financials Summary
As of 31-Jan-2025, Champions Oncology has a trailing 12-month revenue of $58.6M.
|
In Thousands, USD |
TTM 31-Jan-2025 | FY 2024 30-Apr-2024 | FY 2023 30-Apr-2023 | FY 2022 30-Apr-2022 |
|---|---|---|---|---|
| EV | 154,572 | 69,204 | 63,932 | 104,783 |
| Revenue | 58,591 | 50,155 | 53,870 | 49,109 |
| EBITDA | 8,103 | (5,441) | (3,021) | 2,210 |
| Net Income | 6,427 | (7,276) | (5,335) | 548 |
| Total Assets | 30,627 | 26,132 | 34,311 | 35,378 |
| Total Debt | 6,437 | 7,430 | 8,599 | 9,466 |
Champions Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Champions Oncology Comparisons
Industry
Financing
Details
Champions Oncology Competitors (11)
One of Champions Oncology’s 11 competitors is Sygnature Discovery, a Private Equity-Backed company based in Nottingham, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Crown Bioscience | Formerly VC-backed | San Diego, CA | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| ABIONYX Pharma | Formerly VC-backed | Balma, France |
Champions Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Champions Oncology Patents
Champions Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2995574-A1 | Personalized treatment of diseases and disorders | Inactive | 13-Aug-2015 | ||
| US-20180237861-A1 | Personalized treatment of diseases and disorders | Inactive | 13-Aug-2015 | ||
| EP-3335141-A1 | Personalized treatment of diseases and disorders | Inactive | 13-Aug-2015 | ||
| EP-3335141-A4 | Personalized treatment of diseases and disorders | Inactive | 13-Aug-2015 | ||
| EP-3297430-A1 | Humanized mice and uses thereof | Inactive | 22-May-2015 | A61K49/0008 |
Champions Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Champions Oncology Acquisitions (1)
Champions Oncology’s most recent deal was a Merger/Acquisition with Biomerk for . The deal was made on 18-May-2007.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biomerk | 18-May-2007 | Merger/Acquisition | Drug Discovery |
Champions Oncology ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Champions Oncology FAQs
-
When was Champions Oncology founded?
Champions Oncology was founded in 1985.
-
Where is Champions Oncology headquartered?
Champions Oncology is headquartered in Hackensack, NJ.
-
What is the size of Champions Oncology?
Champions Oncology has 306 total employees.
-
What industry is Champions Oncology in?
Champions Oncology’s primary industry is Discovery Tools (Healthcare).
-
Is Champions Oncology a private or public company?
Champions Oncology is a Public company.
-
What is Champions Oncology’s stock symbol?
The ticker symbol for Champions Oncology is CSBR.
-
What is the current stock price of Champions Oncology?
As of 23-Apr-2025 the stock price of Champions Oncology is $8.00.
-
What is the current market cap of Champions Oncology?
The current market capitalization of Champions Oncology is $109M.
-
What is Champions Oncology’s current revenue?
The trailing twelve month revenue for Champions Oncology is $58.6M.
-
Who are Champions Oncology’s competitors?
Sygnature Discovery, Protagonist Therapeutics, Crown Bioscience, AbbVie, and ABIONYX Pharma are some of the 11 competitors of Champions Oncology.
-
What is Champions Oncology’s annual earnings per share (EPS)?
Champions Oncology’s EPS for 12 months was $0.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
